{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:34:50Z","timestamp":1791178490244,"version":"4.1.0"},"reference-count":10,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,7,19]]},"DOI":"10.1182\/blood-2012-04-421016","type":"journal-article","created":{"date-parts":[[2012,7,21]],"date-time":"2012-07-21T05:25:23Z","timestamp":1342848323000},"page":"697-698","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia"],"prefix":"10.1182","volume":"120","author":[{"given":"Sara","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhena","family":"Sergeant","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Department of Haematology, Leeds General Infirmary, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Foroni","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Hedgley","sequence":"additional","affiliation":[{"name":"Department of Haematology, Leeds General Infirmary, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Gerrard","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Stringaris","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Khoder","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alsuliman","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gilleece","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Goldman","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marin","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111808073670700_B1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111808073670700_B2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111808073670700_B3","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2005-05-1897","article-title":"Factors associated with early molecular remission after T cell\u2013depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.","volume":"107","author":"Savani","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019111808073670700_B4","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2005-02-0479","article-title":"The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.","volume":"106","author":"Sconocchia","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2019111808073670700_B5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells.","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111808073670700_B6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/leu.2011.180","article-title":"KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.","volume":"26","author":"Marin","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"2019111808073670700_B7","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111808073670700_B8","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2010-03-273706","article-title":"Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.","volume":"116","author":"Gabriel","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111808073670700_B9","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2008-02-138701","article-title":"Dasatinib suppresses in vitro natural killer cell cytotoxicity.","volume":"111","author":"Blake","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111808073670700_B10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/3\/697\/1362209\/zh802912000697.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/3\/697\/1362209\/zh802912000697.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T08:23:51Z","timestamp":1574065431000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/3\/697\/30479\/Dasatinib-may-overcome-the-negative-prognostic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,19]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-04-421016","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,19]]}}}